L-Phenylalaninamide, N-(1,1-dimethylethoxy)-N2-(1-oxo-3-phenylpropyl)-L-asparaginyl-4-fluoro-N-(1-naphthalenylmethyl)-

DPLG3 is a specific chymotryptic-like β5i subunits inhibitor, with an IC50 of 4.5 nM. DPLG3 inhibits mouse i-20S with IC50 of 9.4 nM. DPLG3 downregulates the protein levels of NF-κB p50 and p65. DPLG3 can be used for immune disease research[1][2][3].

p50; p65

[1] Moallemian R, et al. Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation. Biochem Pharmacol. 2020 Jul;177:113964. DOI:10.1016/j.bcp.2020.113964
[2] Sula Karreci E, et al. Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8425-E8432. DOI:10.1073/pnas.1618548114
[3] Basler M, et al. On the role of the immunoproteasome in transplant rejection. Immunogenetics. 2019 Mar;71(3):263-271. DOI:10.1007/s00251-018-1084-0